Seasonal Conjunctivitis Outbreak Reporting for Prevention and Improved Outcomes (SCORPIO)

项目摘要/摘要 季节性和流行性结膜炎(粉眼)感染具有很高的传染性， 美国和世界范围内的经济负担。可能会出现长期的视力损害。在儿童中， 结膜炎可能预示着更严重的全身并发症，导致住院甚至死亡。 减少疫情的有效机制目前面临的挑战是缺乏跟踪和报告， 获得用于分析的样本收集，诊断测试能力有限，以及不完整 了解所涉及的病原体。该项目的总体目标是结合国际 基因组技术在鉴定病原体、全球趋势、病原体方面的合作努力和进展 进化，以及与结膜炎流行病学有关的免疫反应。我们建议加强 对结膜炎发病机制的认识有以下目的。第一个目标将决定如何 腺病毒基因组类型在一个地区内和不同地区之间有所不同。第二个目标是确定新兴市场 季节性和流行性结膜炎的病因。最后，我们将识别局部免疫应答签名 患有传染性结膜炎的儿童和成人。我们预计结膜基因表达谱将 准确预测疾病相关并发症。这个项目有可能改善公众健康。 监测、指导有针对性的干预、改进疫苗开发和提升现有诊断 结膜炎的范例，以减轻世界范围内的经济和眼睛健康负担。

PROJECT SUMMARY/ABSTRACT Seasonal and epidemic conjunctivitis (pink eye) infections are highly contagious and impose significant economic burden in the United States and worldwide. Long-term visual impairment can occur. In children, conjunctivitis may herald more serious systemic complications leading to hospitalizations and even deaths. Current challenges to effective mechanisms to curtail outbreaks are the lack of tracking and reporting, poor access to sample collection for analysis, limited diagnostic testing capabilities, and an incomplete understanding of the pathogens involved. The overall goal of this project is to combine international collaboration efforts and advances in genomic technologies to identify pathogens, global trends, pathogen evolution, and the immune responses involved in the epidemiology of conjunctivitis. We propose to enhance the understanding of the pathogenesis of conjunctivitis with the following aims. The first aim will determine how adenovirus genome types vary within a region and across regions. The second aim will identify emerging causes of seasonal and epidemic conjunctivitis. Finally, we will identify the local immune response signatures of children and adults with infectious conjunctivitis. We expect that conjunctival gene expression profiles will accurately predict disease associated complications. This project has the potential to improve public health surveillance, guide targeted interventions, improve vaccine development, and elevate existing diagnostic paradigms for conjunctivitis, to reduce both the financial and ocular health burden worldwide.